HK1252685A1 - 用於治疗呼吸疾病的jak激酶抑制剂化合物 - Google Patents

用於治疗呼吸疾病的jak激酶抑制剂化合物 Download PDF

Info

Publication number
HK1252685A1
HK1252685A1 HK18111992.5A HK18111992A HK1252685A1 HK 1252685 A1 HK1252685 A1 HK 1252685A1 HK 18111992 A HK18111992 A HK 18111992A HK 1252685 A1 HK1252685 A1 HK 1252685A1
Authority
HK
Hong Kong
Prior art keywords
treatment
jak kinase
compounds
kinase inhibitor
respiratory disease
Prior art date
Application number
HK18111992.5A
Other languages
English (en)
Chinese (zh)
Inventor
Paul R. Fatheree
John R. Jacobsen
Anne-Marie Beausoleil
Gary E.L. BRANDT
Melissa Fleury
Lan Jiang
Cameron Smith
Steven D.E. Sullivan
Lori Jean Van Orden
Pierre-Jean Colson
Gene Timothy Fass
Miroslav Rapta
Noah Benjamin
Marta Dabros
Venkat R. Thalladi
Original Assignee
Theravance Biopharma R&D Ip, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D Ip, Llc filed Critical Theravance Biopharma R&D Ip, Llc
Publication of HK1252685A1 publication Critical patent/HK1252685A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK18111992.5A 2015-11-03 2016-11-02 用於治疗呼吸疾病的jak激酶抑制剂化合物 HK1252685A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562250113P 2015-11-03 2015-11-03
US62/250,113 2015-11-03

Publications (1)

Publication Number Publication Date
HK1252685A1 true HK1252685A1 (zh) 2019-05-31

Family

ID=57442794

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18111992.5A HK1252685A1 (zh) 2015-11-03 2016-11-02 用於治疗呼吸疾病的jak激酶抑制剂化合物

Country Status (22)

Country Link
US (6) US10100049B2 (enExample)
EP (1) EP3371186A1 (enExample)
JP (1) JP6800969B2 (enExample)
KR (1) KR20180073687A (enExample)
CN (1) CN108349972B (enExample)
AU (1) AU2016350816B2 (enExample)
BR (1) BR112018008966B1 (enExample)
CA (1) CA3001542C (enExample)
CL (1) CL2018001145A1 (enExample)
CO (1) CO2018005640A2 (enExample)
EA (1) EA034914B1 (enExample)
HK (1) HK1252685A1 (enExample)
IL (1) IL258772B (enExample)
MX (1) MX374605B (enExample)
MY (1) MY195427A (enExample)
NZ (1) NZ741737A (enExample)
PH (1) PH12018500828B1 (enExample)
SA (1) SA518391470B1 (enExample)
TW (1) TWI710560B (enExample)
UA (1) UA123633C2 (enExample)
WO (1) WO2017079205A1 (enExample)
ZA (1) ZA201802496B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017079205A1 (en) 2015-11-03 2017-05-11 Theravance Biopharma R&D Ip, Llc Jak kinase inhibitor compounds for treatment of respiratory disease
EP3712152B1 (en) 2015-11-03 2021-01-13 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
WO2017077288A1 (en) 2015-11-03 2017-05-11 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
JP6974487B2 (ja) 2017-03-09 2021-12-01 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー ４員ヘテロ環式アミドを含むｊａｋ阻害剤
US10406148B2 (en) * 2017-05-01 2019-09-10 Theravance Biopharma R&D Ip, Llc Methods of treatment using a JAK inhibitor compound
TWI808083B (zh) * 2017-05-01 2023-07-11 美商施萬生物製藥研發 Ip有限責任公司 Jak抑制劑化合物之結晶型式
AR111495A1 (es) 2017-05-01 2019-07-17 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak
EP3713545A1 (en) 2017-11-22 2020-09-30 Dauntless 1, Inc. Therapeutic compound formulations
US12171764B2 (en) 2018-06-20 2024-12-24 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a JAK or other kinase inhibitor
SG11202101751XA (en) 2018-09-04 2021-03-30 Theravance Biopharma R&D Ip Llc 5 to 7 membered heterocyclic amides as jak inhibitors
BR112021004052A2 (pt) 2018-09-04 2021-05-25 Theravance Biopharma R&D Ip, Llc amidas de dimetil-amino azetidina como inibidores de jak
WO2020051135A1 (en) 2018-09-04 2020-03-12 Theravance Biopharma R&D Ip, Llc Process for preparing jak inhibitors and intermediates thereof
MX2021004582A (es) * 2018-10-29 2021-06-15 Theravance Biopharma R&D Ip Llc Compuesto 2-azabiciclo hexano inhibidor de jak.
US12209092B2 (en) 2018-11-19 2025-01-28 New York University Inhibitors of GLI1 as therapeutic agents
MX2021010242A (es) 2019-02-25 2021-09-21 Henan Medinno Pharmaceutical Tech Co Ltd Compuesto inhibidor de jak y uso del mismo.
CN114075200A (zh) * 2020-08-14 2022-02-22 河南迈英诺医药科技有限公司 用于治疗重症肺炎的jak抑制剂化合物
JP2022524997A (ja) 2019-03-05 2022-05-11 インサイト・コーポレイション 慢性肺同種移植片機能不全の治療のためのｊａｋ１経路阻害剤
KR20210142154A (ko) 2019-03-21 2021-11-24 옹쎄오 암 치료를 위한 키나제 억제제와 조합된 dbait 분자
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
CN113121509B (zh) * 2019-12-30 2024-04-26 河南迈英诺医药科技有限公司 Jak抑制剂化合物及其用途
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
TW202144343A (zh) 2020-03-02 2021-12-01 美商施萬生物製藥研發 Ip有限責任公司 Jak抑制劑化合物之結晶水合物
WO2022178215A1 (en) * 2021-02-19 2022-08-25 Theravance Biopharma R&D Ip, Llc Amino amide tetrahydro imidazo pyridines as jak inhibitors
CN117083273A (zh) 2021-03-26 2023-11-17 施万生物制药研发Ip有限责任公司 Jak抑制剂化合物的二盐酸盐的晶型
TW202317550A (zh) 2021-06-25 2023-05-01 美商施萬生物製藥研發 Ip有限責任公司 作為jak抑制劑之咪唑吲唑化合物
CN114181055A (zh) * 2021-12-21 2022-03-15 苏州楚凯药业有限公司 1-苄氧基-4-溴-5-乙基-2-氟苯的制备方法
JP2025515078A (ja) 2022-05-05 2025-05-13 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー 噴霧経口吸入による送達のためのネズルシチニブ

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
US7872014B2 (en) 2003-07-23 2011-01-18 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
US20050090529A1 (en) 2003-07-31 2005-04-28 Pfizer Inc 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
US7884109B2 (en) 2005-04-05 2011-02-08 Wyeth Llc Purine and imidazopyridine derivatives for immunosuppression
WO2008049123A2 (en) 2006-10-19 2008-04-24 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine derivatives as inhibitors of jak kinases for the treatment of autoimmune diseases
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
CA2727036C (en) 2008-06-20 2017-03-21 Genentech, Inc. Triazolopyridine jak inhibitor compounds and methods
US20110184013A1 (en) 2008-10-01 2011-07-28 Shelley Allen Imidazo[1,2-a]Pyridine Compounds As Receptor Tyrosine Kinase Inhibitors
CL2009001884A1 (es) * 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
JP2010111624A (ja) 2008-11-06 2010-05-20 Shionogi & Co Ltd Ｔｔｋ阻害作用を有するインダゾール誘導体
US20120029190A1 (en) 2009-04-03 2012-02-02 Douglas Burdi Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
CN102470135A (zh) 2009-07-28 2012-05-23 里格尔药品股份有限公司 抑制jak途径的组合物和方法
LT3001903T (lt) * 2009-12-21 2018-01-10 Samumed, Llc 1h-pirazolo[3,4-b]piridinai ir jų terapinis panaudojimas
EP2338888A1 (en) 2009-12-24 2011-06-29 Almirall, S.A. Imidazopyridine derivatives as JAK inhibitors
CN103476770B (zh) 2010-11-25 2017-02-15 拉蒂欧制药有限责任公司 阿法替尼盐和多晶型物
US8575336B2 (en) * 2011-07-27 2013-11-05 Pfizer Limited Indazoles
PH12017500997A1 (en) 2012-04-04 2018-02-19 Samumed Llc Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
TW201513861A (zh) * 2013-01-17 2015-04-16 Galapagos Nv 用於治療退化性及發炎疾病之新穎化合物
MD4649C1 (ro) 2013-12-05 2020-04-30 Pfizer Inc. Pirol[2,3-d]pirimidinil, pirol[2,3-b]pirazinil şi pirol[2,3-d]piridinil acrilamide
PE20161475A1 (es) 2014-05-14 2017-01-08 Pfizer Pirazolopiridinas y pirazolopirimidinas
WO2016026078A1 (en) 2014-08-19 2016-02-25 Changzhou Jiekai Pharmatech Co., Ltd. Heterocyclic compounds as erk inhibitors
KR101663277B1 (ko) 2015-03-30 2016-10-06 주식회사 녹십자 TNIK, IKKε 및 TBK1 억제제로서의 피라졸계 유도체 및 이를 포함하는 약학적 조성물
WO2017077288A1 (en) 2015-11-03 2017-05-11 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
EP3712152B1 (en) 2015-11-03 2021-01-13 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
WO2017079205A1 (en) 2015-11-03 2017-05-11 Theravance Biopharma R&D Ip, Llc Jak kinase inhibitor compounds for treatment of respiratory disease
JP6974487B2 (ja) 2017-03-09 2021-12-01 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー ４員ヘテロ環式アミドを含むｊａｋ阻害剤
US10406148B2 (en) 2017-05-01 2019-09-10 Theravance Biopharma R&D Ip, Llc Methods of treatment using a JAK inhibitor compound
AR111495A1 (es) 2017-05-01 2019-07-17 Theravance Biopharma R&D Ip Llc Compuestos de imidazo-piperidina fusionada como inhibidores de jak
TWI808083B (zh) 2017-05-01 2023-07-11 美商施萬生物製藥研發 Ip有限責任公司 Jak抑制劑化合物之結晶型式
SG11202101751XA (en) 2018-09-04 2021-03-30 Theravance Biopharma R&D Ip Llc 5 to 7 membered heterocyclic amides as jak inhibitors
WO2020051135A1 (en) 2018-09-04 2020-03-12 Theravance Biopharma R&D Ip, Llc Process for preparing jak inhibitors and intermediates thereof
BR112021004052A2 (pt) 2018-09-04 2021-05-25 Theravance Biopharma R&D Ip, Llc amidas de dimetil-amino azetidina como inibidores de jak
MX2021004582A (es) 2018-10-29 2021-06-15 Theravance Biopharma R&D Ip Llc Compuesto 2-azabiciclo hexano inhibidor de jak.
CN117083273A (zh) 2021-03-26 2023-11-17 施万生物制药研发Ip有限责任公司 Jak抑制剂化合物的二盐酸盐的晶型

Also Published As

Publication number Publication date
CN108349972A (zh) 2018-07-31
WO2017079205A1 (en) 2017-05-11
BR112018008966A2 (pt) 2018-11-27
AU2016350816A1 (en) 2018-05-17
CL2018001145A1 (es) 2018-07-06
EP3371186A1 (en) 2018-09-12
PH12018500828B1 (en) 2023-06-30
US11718616B2 (en) 2023-08-08
EA201891091A1 (ru) 2018-12-28
US20170121327A1 (en) 2017-05-04
TWI710560B (zh) 2020-11-21
TW201726673A (zh) 2017-08-01
KR20180073687A (ko) 2018-07-02
JP6800969B2 (ja) 2020-12-16
JP2018531982A (ja) 2018-11-01
BR112018008966B1 (pt) 2023-05-02
SA518391470B1 (ar) 2021-03-31
PH12018500828A1 (en) 2018-10-29
NZ741737A (en) 2023-11-24
US20200087303A1 (en) 2020-03-19
CN108349972B (zh) 2021-06-08
US20220306624A1 (en) 2022-09-29
US20190106420A1 (en) 2019-04-11
EA034914B1 (ru) 2020-04-06
IL258772A (en) 2018-06-28
US11299492B2 (en) 2022-04-12
UA123633C2 (uk) 2021-05-05
US10100049B2 (en) 2018-10-16
CO2018005640A2 (es) 2018-05-31
IL258772B (en) 2021-01-31
AU2016350816B2 (en) 2020-06-25
ZA201802496B (en) 2025-01-29
US10526330B2 (en) 2020-01-07
US10913740B2 (en) 2021-02-09
MX374605B (es) 2025-03-06
MX2018005446A (es) 2018-08-01
US20210130351A1 (en) 2021-05-06
US20180319796A1 (en) 2018-11-08
US10183942B2 (en) 2019-01-22
MY195427A (en) 2023-01-20
CA3001542A1 (en) 2017-05-11
CA3001542C (en) 2021-02-16

Similar Documents

Publication Publication Date Title
HK1252685A1 (zh) 用於治疗呼吸疾病的jak激酶抑制剂化合物
PH12019501985A1 (en) Fused imidazo-piperidine jak inhibitors
PH12017502050A1 (en) Naphthyridine compounds as jak kinase inhibitors
SG10201811384TA (en) Mnk inhibitors and methods related thereto
MX375674B (es) Compuestos de carboxamida inhibidores de la actividad de cinasa rip2.
WO2015168466A8 (en) Inhibitors of lysine specific demethylase-1
TN2016000268A1 (en) N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2.
MD4800B1 (ro) Compuşi de aminopirimidinil ca inhibitori de JAK
EA201791576A1 (ru) Ингибитор jak
MY197440A (en) Heteroamatic compounds as btk inhibitors
PH12019500497A1 (en) Heteroaryl carboxamide compounds as inhibitors of ripk2
PH12016501462A1 (en) Neprilysin inhibitors
MX2019014876A (es) Compuestos heteroaromaticos como inhibidores de vanina.
WO2016004404A3 (en) Gls1 inhibitors for treating disease
WO2016004413A3 (en) Gls1 inhibitors for treating disease
MX2019006863A (es) Inhibidores de heparanasa y uso de los mismos.
PH12017500558A1 (en) 4'-vinyl substituted nucleoside derivatives as inhibitors of respiratory syncytial virus rna replication
EA201792265A1 (ru) Способы лечения сердечно-сосудистых заболеваний
EA201990686A1 (ru) Нафтиридиновые соединения в качестве ингибиторов jak киназы
HK1231074A1 (en) Neprilysin inhibitors